The current formulary-driven switch, in contrast, represents a payer-initiated formulary shift rather than a supply-side limitation
New FDA policy on compounding GLP-1 drugs New FDA policy on compounding GLP-1 drugs On April 24, 2025, FDA announced that licensed pharmacies and physicians can no longer compound semaglutide (a GLP-1 drug used in Ozempic & Wegovy) and outsourcing facilities must stop production by May 22, 2025
Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American college of cardiology/American heart association Task Force on Clinical practice guidelines
The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the prophylactic medicaments containing insulin landscape in the United States